PTC Therapeutics 配当と自社株買い
配当金 基準チェック /06
PTC Therapeutics配当金を支払った記録がありません。
主要情報
n/a
配当利回り
-1.9%
バイバック利回り
| 総株主利回り | -1.9% |
| 将来の配当利回り | 0% |
| 配当成長 | n/a |
| 次回配当支払日 | n/a |
| 配当落ち日 | n/a |
| 一株当たり配当金 | n/a |
| 配当性向 | n/a |
最近の配当と自社株買いの更新
更新なし
Recent updates
ナラティブ更新 • Aug 17
PTCT: Fabry Gene Therapy Deal And Pipeline Concentration Will Shape Future Upside
Analysts increased their price targets for PTC Therapeutics and the updated fair value estimate moved from $65.00 to $70.00, citing stronger perceived potential for Sephience, the recent ST-920 acquisition for $111.00 million, and ongoing interest in the pipeline, including Fabry and votoplam related programs. Analyst Commentary Recent research on PTC Therapeutics has stayed broadly constructive, with most firms lifting price targets and highlighting the role of Sephience and the broader pipeline in their models.
ナラティブ更新 • Aug 03
PTCT: Rare Disease Franchise And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have raised their blended price target on PTC Therapeutics by about $3 to roughly $97, citing updated views on Sephience's commercial ramp, revised assumptions for profit margins, and adjusted expectations for future P/E multiples reflected in recent research from multiple firms. Analyst Commentary Recent research on PTC Therapeutics points to a cluster of higher price targets and supportive views on Sephience and the broader pipeline.
ナラティブ更新 • Jul 20
PTCT: Future Earnings Power Will Be Driven By Expanding Rare Disease Pipeline
Analysts have lifted their fair value estimate for PTC Therapeutics to $129.21 from $121.11, reflecting updated assumptions that balance stronger revenue growth expectations and higher future P/E multiples with more tempered profit margin forecasts, supported by recent Street research highlighting the commercial potential of Sephience and the broader pipeline. Analyst Commentary Recent Street research on PTC Therapeutics points to a more constructive tone, with several bullish analysts updating their models to reflect what they see as underappreciated commercial potential for Sephience and selected pipeline assets.ナラティブ更新 • Jul 06
PTCT: Single-Drug Dependence Will Likely Cap Upside Despite Rising Optimism
The analyst price target for PTC Therapeutics has been raised from $55 to $65, as analysts point to stronger modeled revenue growth, higher expected profit margins, and a lower future P/E multiple supported by recent bullish research highlighting Sephience expectations. Analyst Commentary Recent research on PTC Therapeutics shows a mix of optimism around Sephience and caution around how that potential is reflected in the stock.Seeking Alpha • Jun 23
The Prognosis For PTC Therapeutics
Summary PTC Therapeutics has surged 75% since Sephience’s July 2025 approval, driven by a blockbuster launch and robust sales momentum. Sephience’s superior efficacy, broad label, and rapid uptake support management’s $2 billion peak sales target, with 1Q26 sales reaching $124.6 million. PTCT’s balance sheet is fortified by $1.89 billion in cash and a lucrative Novartis collaboration, providing optionality for business development. An analysis around PTC Therapeutics follows in the paragraphs below. Read the full article on Seeking Alphaナラティブ更新 • Jun 22
PTCT: Strong Rare Disease Franchise Will Support Bullish 2026 Outlook
Analysts have nudged their fair value estimate for PTC Therapeutics higher, with the updated price target rising by about $2.36. They cite refined patient build models and expectations for Sephience revenues that they view as stronger than current consensus, along with improved margin forecasts and a lower assumed future P/E.分析記事 • Jun 18
PTC Therapeutics (PTCT) Stock Could Be 14% Undervalued After $500 Million Note Refinancing
PTC Therapeutics (PTCT) has drawn fresh attention after launching a $500 million private placement of 0% convertible senior notes due 2031, aimed at refinancing existing 2026 convertible debt and supporting general corporate needs. See our latest analysis for PTC Therapeutics. PTC Therapeutics shares have been volatile around the $78.53 level, with a 1-day share price return of 7.18% and a 90-day share price return of 17.08%, while the 1-year total shareholder return of 55.72% points to...ナラティブ更新 • Jun 05
PTCT: Refined Rare Disease Models Will Support Huntington Progress Toward Bullish 2026 Outlook
The analyst price target for PTC Therapeutics has increased by about $0.64, with analysts citing refreshed patient build models for Sephience and updated assumptions for growth, margins, and future P/E as the reasons for the slightly higher fair value estimate. Analyst Commentary Recent Street research around PTC Therapeutics has focused on how Sephience inputs feed into long term revenue build outs, margin profiles, and the multiples analysts are willing to use in their fair value work.ナラティブ更新 • May 19
PTCT: Early Neurology Execution Will Drive Huntington Progress Toward Bullish 2026 Outlook
Analysts have nudged their average price target on PTC Therapeutics higher, from about $88 to roughly $91, reflecting updated models that factor in stronger projected revenue growth, higher expected profit margins, and a lower assumed discount rate, alongside Street research that has largely raised or reaffirmed positive price targets following recent Q4 results and Sephience launch commentary. Analyst Commentary Recent Street research on PTC Therapeutics reflects a mix of optimism around the Sephience launch and revenue outlook, alongside some caution on execution risks and prior franchises.分析記事 • May 16
Analyst Forecasts For PTC Therapeutics, Inc. (NASDAQ:PTCT) Are Surging Higher
PTC Therapeutics, Inc. ( NASDAQ:PTCT ) shareholders will have a reason to smile today, with the analysts making...ナラティブ更新 • May 03
PTCT: Early Neurology Launch And Huntington Progress Will Support Bullish 2026 Outlook
Analyst fair value for PTC Therapeutics has edged up by about $0.20 as analysts incorporate slightly less severe revenue declines, higher expected profitability, and a lower future P/E into their updated models following recent Q4 commentary and new coverage initiations. Analyst Commentary Street research on PTC Therapeutics over the past few months has centered on how Q4 results, early Sephience data, and franchise mix shape the earnings outlook and what that implies for fair value.ナラティブ更新 • Apr 19
PTCT: Early Neurology Launch And Pipeline Progress Will Support Bullish 2026 Outlook
Analysts have nudged their average price target for PTC Therapeutics higher to about $88 from roughly $86.50. This reflects updates to models after recent Q4 commentary, revised views on revenue trends, margin expectations, and future P/E assumptions.ナラティブ更新 • Apr 05
PTCT: Early Neurology Launch Execution Will Drive Bullish 2026 Outlook
Narrative Update on PTC Therapeutics The analyst price target for PTC Therapeutics has been trimmed from $87.93 to $86.50 as analysts balance generally higher Street targets and improved profit margin assumptions with slightly softer revenue growth expectations and a more conservative future P/E. Analyst Commentary Recent research updates on PTC Therapeutics show a mix of optimism and caution, with several analysts adjusting price targets after the Q4 report, Sephience launch updates, and broader sector views.ナラティブ更新 • Mar 22
PTCT: Future Earnings Power Will Be Driven By Growing PKU And Huntington’s Pipelines
Analysts have raised PTC Therapeutics' consensus price target from the low $90s to around $120, citing updated Q4 results, early Sephience traction, and expectations that newer revenue streams could offset pressure in the DMD franchise. Analyst Commentary Recent research on PTC Therapeutics has leaned constructive, with several bullish analysts tying higher valuation ranges to execution around Sephience, updated Q4 commentary, and the broader revenue mix.ナラティブ更新 • Mar 07
PTCT: Future Earnings Power Will Be Driven By Expanding PKU And Huntington’s Franchises
The analyst price target for PTC Therapeutics has been raised by $6.61, with analysts pointing to stronger modeled revenue growth, higher profit margins, and updated P/E assumptions following recent Q4 commentary and comparative advantages in Huntington's disease treatments. Analyst Commentary Recent Street research around PTC Therapeutics has been broadly constructive, with several bullish analysts adjusting their models after the Q4 update and early Sephience launch commentary.ナラティブ更新 • Feb 21
PTCT: Sephience Execution Will Drive Bullish 2026 Outlook Despite DMD Pressure
Narrative Update: PTC Therapeutics The analyst price target for PTC Therapeutics has shifted modestly lower to align with our updated fair value of about $87.93, as analysts weigh mixed revisions to revenue growth and profitability assumptions against ongoing support from Sephience-driven estimates. Analyst Commentary Recent Street research on PTC Therapeutics centers on how Sephience trends could influence the company’s revenue mix, profitability path, and valuation, especially as the DMD franchise faces pressure.ナラティブ更新 • Feb 06
PTCT: Index Additions And Pipeline Execution Will Shape Bullish 2026 Outlook
Analysts have raised their fair value estimate for PTC Therapeutics to about $88.50 from $81.86, reflecting updated views on the discount rate, revenue trends, profit expectations, and a higher assumed future P/E that aligns with recent price target increases from several research firms. Analyst Commentary Recent Street research on PTC Therapeutics has focused on price target adjustments and rating changes, which feed directly into how analysts think about valuation, execution risk, and potential growth opportunities.ナラティブ更新 • Jan 23
PTCT: Single-Drug Dependence Will Likely Limit Upside Despite Strong Launch Start
Narrative Update: PTC Therapeutics (PTCT) The analyst price target for PTC Therapeutics is updated in line with a series of upward Street revisions, as analysts point to stronger than expected Sephience launch metrics and recent Q3 outperformance, along with generally supportive views on small to mid cap biotech heading into 2026. Analyst Commentary Street research on PTC Therapeutics has leaned positive around the Q3 report and the Sephience launch, with several large firms lifting price targets after what they describe as strong initial commercial execution.ナラティブ更新 • Jan 08
PTCT: Future Earnings Power Will Be Driven By Expanding PKU Franchise
The analyst price target for PTC Therapeutics has been raised from about $103 to about $115. Analysts cited stronger Sephience launch trends, a shift in the modeled profit margin to 34%, a more moderate future P/E near 20x, and a less conservative revenue outlook as key drivers of the change.ナラティブ更新 • Dec 25
PTCT Overreliance On Single Drug Will Likely Cap Share Price Upside
The analyst fair value estimate for PTC Therapeutics has been raised from $44.00 to $55.00 per share as analysts factor in stronger than expected Sephience launch metrics, upwardly revised price targets across the Street, and improving confidence in the durability of the company’s growth trajectory. Analyst Commentary Recent Street research has broadly welcomed PTC Therapeutics Q3 performance and the stronger than expected Sephience launch, with several major firms lifting their price targets.ナラティブ更新 • Dec 11
PTCT: Launch Momentum And Index Additions Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by about $1.36 to roughly $81.86, as analysts highlight stronger than expected Sephience launch metrics, improving revenue and margin assumptions, and sustained post earnings momentum. Analyst Commentary Analysts are broadly constructive on PTC Therapeutics following its latest earnings, citing Sephience outperformance and improving visibility into the company’s growth trajectory.ナラティブ更新 • Nov 27
PTCT: Revenue Outlook And New Launch Performance Will Influence 2025 Assessment
Analysts have raised their price target for PTC Therapeutics from approximately $77.93 to $80.50, citing stronger-than-expected Sephience sales and continued momentum following the company's latest earnings report. Analyst Commentary Recent reports from Wall Street analysts reflect a range of views regarding PTC Therapeutics' execution and growth prospects, primarily driven by the company's strong recent earnings and the launch of Sephience.ナラティブ更新 • Nov 11
PTCT: Revenue Guidance Narrowing And Launch Momentum Will Shape 2025 Outlook
The analyst price target for PTC Therapeutics has been raised by $10, as analysts cite stronger-than-expected Sephience sales and increasing momentum following the company's recent earnings beat. Analyst Commentary Recent analyst reports on PTC Therapeutics highlight a wide range of perspectives following the company’s robust third-quarter results and new product launches.ナラティブ更新 • Oct 28
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Analysts have increased their average price target for PTC Therapeutics by approximately $1.25 to $67.93. They cite heightened community interest in Sephience, improved profit margin forecasts, and overall strong sentiment for upcoming launches, despite recent regulatory setbacks.ナラティブ更新 • Aug 27
Broad Approvals Will Elevate Rare Disease Markets Despite Setbacks
Analysts lowered their price targets for PTC Therapeutics following the FDA's Complete Response Letter for vatiquinone, citing the removal of Friedreich's ataxia revenues and increased regulatory uncertainty, though encouraging early signals from the Sephience launch and its broad approval label partially offset downside, resulting in a modest consensus target reduction from $68.31 to $66.69. Analyst Commentary Bullish analysts highlight the recent selloff post-FDA Complete Response Letter (CRL) for vatiquinone in Friedreich's ataxia as a buying opportunity, believing negative outcomes were anticipated and already priced into shares.
新しいナラティブ • Mar 21
2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs
Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues.決済の安定と成長
配当データの取得
安定した配当: PTCTの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。
増加する配当: PTCTの配当金が増加しているかどうかを判断するにはデータが不十分です。
配当利回り対市場
| PTC Therapeutics 配当利回り対市場 |
|---|
| セグメント | 配当利回り |
|---|---|
| 会社 (PTCT) | n/a |
| 市場下位25% (US) | 1.4% |
| 市場トップ25% (US) | 4.1% |
| 業界平均 (Biotechs) | 2.2% |
| アナリスト予想 (PTCT) (最長3年) | 0% |
注目すべき配当: PTCTは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。
高配当: PTCTは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。
株主への利益配当
収益カバレッジ: PTCTの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。
株主配当金
キャッシュフローカバレッジ: PTCTが配当金を報告していないため、配当金の持続可能性を計算できません。
高配当企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/14 13:06 |
| 終値 | 2026/09/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
PTC Therapeutics, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。33
| アナリスト | 機関 |
|---|---|
| Joel Beatty | Baird |
| Luke Herrmann | Baird |
| null null | Baird |